Purpose The characteristic MRI features of multiple sclerosis (MS) lesions make it conceptually appealing to pursue parametric mapping techniques that support simultaneous generation of quantitative maps of 2 or more MR contrast mechanisms. We present a modular rapid acquisition with relaxation enhancement (RARE)‐EPI hybrid that facilitates simultaneous T2 and mapping (2in1‐RARE‐EPI). Methods In 2in1‐RARE‐EPI the first echoes in the echo train are acquired with a RARE module, later echoes are acquired with an EPI module. To define the fraction of echoes covered by the RARE and EPI module, an error analysis of T2 and was conducted with Monte Carlo simulations. Radial k‐space (under)sampling was implemented for acceleration (R = 2). The feasibility of 2in1‐RARE‐EPI for simultaneous T2 and mapping was examined in a phantom study mimicking T2 and relaxation times of the brain. For validation, 2in1‐RARE‐EPI was benchmarked versus multi spin‐echo (MSE) and multi gradient‐echo (MGRE) techniques. The clinical applicability of 2in1‐RARE‐EPI was demonstrated in healthy subjects and MS patients. Results There was a good agreement between T2/ values derived from 2in1‐RARE‐EPI and T2/ reference values obtained from MSE and MGRE in both phantoms and healthy subjects. In patients, MS lesions in T2 and maps deduced from 2in1‐RARE‐EPI could be just as clearly delineated as in reference maps calculated from MSE/MGRE. Conclusion This work demonstrates the feasibility of radially (under)sampled 2in1‐RARE‐EPI for simultaneous T2 and mapping in MS patients.
Case reports indicate that magnets in smartphones could be a source of electromagnetic interference (EMI) for active implantable medical devices (AIMD), which could lead to device malfunction, compromising patient safety. Recognizing this challenge, we implemented a high-fidelity 3D magnetic field mapping (spatial resolution 1 mm) setup using a three-axis Hall probe and teslameter, controlled by a robot (COSI Measure). With this setup, we examined the stray magnetic field of an iPhone 13 Pro, iPhone 12, and MagSafe charger to identify sources of magnetic fields for the accurate risk assessment of potential interferences with AIMDs. Our measurements revealed that the stray fields of the annular array of magnets, the wide-angle camera, and the speaker of the smartphones exceeded the 1 mT limit defined by ISO 14117:2019. Our data-driven safety recommendation is that an iPhone 13 Pro should be kept at least 25 mm away from an AIMD to protect it from unwanted EMI interactions. Our study addresses safety concerns due to potential device–device interactions between smartphones and AIMDs and will help to define data-driven safety guidelines. We encourage vendors of electronic consumer products (ECP) to provide information on the magnetic fields of their products and advocate for the inclusion of smartphones in the risk assessment of EMI with AIMDs.
(1) Background: Radial RARE-EPI MRI facilitates simultaneous T2 and T2* mapping (2in1-RARE-EPI). With modest undersampling (R = 2), the speed gain of 2in1-RARE-EPI relative to Multi-Spin-Echo and Multi-Gradient-Recalled-Echo references is limited. Further reduction in scan time is crucial for clinical studies investigating T2 and T2* as imaging biomarkers. We demonstrate the feasibility of further acceleration, utilizing compressed sensing (CS) reconstruction of highly undersampled 2in1-RARE-EPI. (2) Methods: Two-fold radially-undersampled 2in1-RARE-EPI data from phantoms, healthy volunteers (n = 3), and multiple sclerosis patients (n = 4) were used as references, and undersampled (Rextra = 1–12, effective undersampling Reff = 2–24). For each echo time, images were reconstructed using CS-reconstruction. For T2 (RARE module) and T2* mapping (EPI module), a linear least-square fit was applied to the images. T2 and T2* from CS-reconstruction of undersampled data were benchmarked against values from CS-reconstruction of the reference data. (3) Results: We demonstrate accelerated simultaneous T2 and T2* mapping using undersampled 2in1-RARE-EPI with CS-reconstruction is feasible. For Rextra = 6 (TA = 01:39 min), the overall MAPE was ≤8% (T2*) and ≤4% (T2); for Rextra = 12 (TA = 01:06 min), the overall MAPE was <13% (T2*) and <5% (T2). (4) Conclusion: Substantial reductions in scan time are achievable for simultaneous T2 and T2* mapping of the brain using highly undersampled 2in1-RARE-EPI with CS-reconstruction.
Purpose: To demonstrate the synergy of undersampled radial 2in1‐RARE‐EPI acquisition and nonlinear model‐based reconstruction for accelerated and simultaneous T2 , T2 *, and R2 ′ mapping in brains of patients with multiple sclerosis (MS). Methods: 2in1‐RARE‐EPI combines a RARE module with an EPI module to capture T2 and T2 * information. Nonlinear model‐based reconstruction was applied to estimate T2 , T2 * maps directly from undersampled k ‐space data. A retrospective undersampling experiment was conducted to compare nonlinear model‐based and parallel imaging compressed sensing (PICS) reconstruction. The proposed approach was validated and compared to reference methods multiecho spin‐echo ( T2 , MSE) and multiecho gradient‐echo ( T2 *, MGRE) in a phantom, healthy subjects, and MS patients. Results: 2in1‐RARE‐EPI together with nonlinear model‐based reconstruction enabled T2 , T2 *, and R2 ′ mapping with 7.5‐fold scan‐time acceleration relative to the references, while addressing key limitations of reference techniques, including long acquisition times, misregistration, motion and off‐resonance sensitivity, and the need for calibration scans. Phantom and in vivo validation showed that the parametric maps obtained with this approach were in agreement with the reference methods. Compared with PICS, nonlinear model‐based reconstruction showed more consistent spatial detail and accuracy at higher acceleration factors. The proposed method detected small focal lesions in T2 , T2 *, and R2 ′ maps of MS patients and enabled visualization of the central vein sign. Conclusion: Scan time reduction facilitated by nonlinear model‐based reconstruction of 2in1‐RARE‐EPI provides a technical foundation for enhanced patient compliance, and is a fundamental precursor for broader clinical studies on the potential of T2 , T2 *, and R2 ′ as imaging biomarkers.